Tanvex BioPharma Inc (6541) - Total Assets
Based on the latest financial reports, Tanvex BioPharma Inc (6541) holds total assets worth NT$8.18 Billion TWD (≈ $257.56 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 6541 net asset value for net asset value and shareholders' equity analysis.
Tanvex BioPharma Inc - Total Assets Trend (2013–2024)
This chart illustrates how Tanvex BioPharma Inc's total assets have evolved over time, based on quarterly financial data.
Tanvex BioPharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tanvex BioPharma Inc's total assets of NT$8.18 Billion consist of 24.7% current assets and 75.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 13.8% |
| Accounts Receivable | NT$939.00K | 0.0% |
| Inventory | NT$217.84 Million | 8.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$7.07 Million | 0.3% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Tanvex BioPharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 6541 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tanvex BioPharma Inc's current assets represent 24.7% of total assets in 2024, a decrease from 37.5% in 2013.
- Cash Position: Cash and equivalents constituted 13.8% of total assets in 2024, down from 34.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 8.0% of total assets.
Tanvex BioPharma Inc Competitors by Total Assets
Key competitors of Tanvex BioPharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Tanvex BioPharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.97 | 2.62 | 6.41 |
| Quick Ratio | 2.39 | 2.25 | 6.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.37 Billion | NT$578.42 Million | NT$1.91 Billion |
Tanvex BioPharma Inc - Advanced Valuation Insights
This section examines the relationship between Tanvex BioPharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -1.0% |
| Total Assets | NT$2.74 Billion |
| Market Capitalization | $330.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tanvex BioPharma Inc's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Tanvex BioPharma Inc's assets decreased by 1.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Tanvex BioPharma Inc (2013–2024)
The table below shows the annual total assets of Tanvex BioPharma Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.74 Billion ≈ $86.17 Million |
-1.02% |
| 2023-12-31 | NT$2.76 Billion ≈ $87.06 Million |
-19.19% |
| 2022-12-31 | NT$3.42 Billion ≈ $107.74 Million |
-27.45% |
| 2021-12-31 | NT$4.71 Billion ≈ $148.50 Million |
+7.80% |
| 2020-12-31 | NT$4.37 Billion ≈ $137.76 Million |
+22.38% |
| 2019-12-31 | NT$3.57 Billion ≈ $112.57 Million |
-20.22% |
| 2018-12-31 | NT$4.48 Billion ≈ $141.11 Million |
+12.73% |
| 2017-12-31 | NT$3.97 Billion ≈ $125.17 Million |
+2.60% |
| 2016-12-31 | NT$3.87 Billion ≈ $122.00 Million |
+146.74% |
| 2015-12-31 | NT$1.57 Billion ≈ $49.45 Million |
+139.70% |
| 2014-12-31 | NT$654.74 Million ≈ $20.63 Million |
+34.37% |
| 2013-12-31 | NT$487.27 Million ≈ $15.35 Million |
-- |
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that… Read more